Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Madrigal Pharmaceuticals Inc.
Headquarters: Conshohocken, PA, United States of America
Website: http://www.madrigalpharma.com...
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: William J. Sibold, MBA
Number Of Employees: 528
Enterprise Value: $5,752,516,884
PE Ratio: -15.26
Exchange/Ticker 1: NASDAQ:MDGL
Exchange/Ticker 2: N/A
Latest Market Cap: $7,446,989,312
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Jan 18, 2025
Data Byte
Takeout news crowns JPM’s winning stocks
Gainers, decliners among companies presenting at this week’s J.P. Morgan Healthcare Conference
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Dec 13, 2024
Management Tracks
Genesis hires Shifeng Pan as CSO, names Paul Friedman chair
Plus: Gen1E names François Nader chairman, and updates from Iambic and Boundless
BioCentury | Oct 4, 2024
Finance
3Q24 Wrap: Lookin’ up at last
Winners, losers in biotech stock tiers in 3Q24
BioCentury | Oct 2, 2024
Management Tracks
IGM names Mary Beth Harler CEO as it prioritizes T cell engagers
Plus: Ken Mills becomes CEO of Tagworks, and updates from AstronauTx, Trevi, Thrive and Madrigal
BioCentury | Aug 6, 2024
Management Tracks
A trio of hires at 4D
Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more
BioCentury | Apr 25, 2024
Management Tracks
Smart to lead Actym as CEO
Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotech
BioCentury | Apr 19, 2024
Finance
Public equity report: Depression data drive Intra-Cellular’s $500M raise
Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura
BioCentury | Apr 3, 2024
Data Byte
Last minute flurry brings FDA’s first-quarter NME approvals to 10
Highlights include accelerated approval of first MASH therapy; plus Merck’s disease-modifying PAH therapy and Idorsia’s antihypertensive
Items per page:
1 - 10 of 97